Employees: 1,479
Size Mochida Pharmaceutical (4534.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $714M, the 899th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥3,325 on 18 Nov 2026.
Performance Over six months the shares fell 2.6%, against -15.3% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 15.8% over the last twelve months (peer median +3.2%); the operating margin is 9.7% (peer median 9.6%).
Valuation It trades at 16.1× forward earnings against a peer median of 15.2× (6th cheapest of 11).
Capital Return on invested capital runs 1.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥126B | ¥117B | ¥105B | ¥103B | ¥103B |
| Revenue growth | — | +11% | +2% | 0% | — |
| Gross profit | ¥59.5B | ¥56.3B | ¥53.8B | ¥52.1B | ¥55.1B |
| EBITDA | ¥15.7B | ¥13.1B | ¥11.1B | ¥8.61B | ¥11.2B |
| Net income | ¥10.8B | ¥7.90B | ¥5.68B | ¥4.55B | ¥6.65B |
| Free cash flow | n/a | -¥10.0B | ¥7.19B | -¥9.78B | ¥5.13B |
| Capital expenditure | n/a | ¥2.69B | ¥2.16B | ¥2.30B | ¥2.17B |
| Total debt | ¥10.0B | ¥10.3B | ¥342M | ¥369M | ¥190M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4534.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.1% | -8.4% | 3rd highest of 21 |
| 6-month return | -2.6% | -15.3% | 7th highest of 21 |
| Distance from 52-week high | -16.1% | -36.1% | 4th highest of 21 |
| Revenue growth (TTM) | +15.8% | +3.2% | 3rd highest of 19 |
| Operating margin | 9.7% | 9.6% | 9th highest of 19 |
| Forward P/E | 16.1× | 15.2× | 6th cheapest of 11 |
| ROIC minus cost of capital | +1.9 pp | +0.7 pp | 8th highest of 17 |
| EV / EBITDA | 6.1× | 3.6× | 2nd most expensive of 5 |
| Net debt / EBITDA | -1.2× | -1.4× | 2nd most indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mochida Pharmaceutical 4534.T | Japan | $714M | -3% | +16% | 10% | 16.1× | n/a | n/a |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $716M | -31% | -16% | 0% | n/a | n/a | n/a |
| Hunan Fangsheng Pharmaceutical 603998.SS | China | $719M | -1% | +12% | 20% | 13.7× | -4.8% | +6.4% |
| Sagimet Biosciences SGMT | United States | $722M | +52% | n/a | n/a | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $725M | -34% | -3% | 9% | 47.6× | n/a | n/a |
| Shanghai Jiaoda Onlly 600530.SS | China | $726M | -25% | -2% | -2% | n/a | 42.7% | -0.9% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $727M | -9% | +8% | 26% | 11.2× | 5.9% | +11.3% |
| HPGC Renmintongtai Pharmaceutical 600829.SS | China | $701M | -6% | +4% | 2% | n/a | 4.0% | +5.3% |
| Nuvectis Pharma NVCT | United States | $698M | +91% | n/a | n/a | n/a | n/a | n/a |
| Luye Pharma 2186.HK | Hong Kong | $736M | -32% | +3% | 18% | 7.1× | -11.8% | +1.9% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $738M | -20% | -5% | 13% | 16.7× | -2.0% | +26.1% |
| Earth 4985.T | Japan | $687M | +7% | +4% | 4% | 18.0× | -1.6% | -1.8% |
| Shandong Wit Dyne Health 000915.SZ | China | $687M | -31% | -36% | 36% | 9.1× | n/a | n/a |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $746M | -3% | +4% | 11% | n/a | -2.1% | 0.0% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $751M | -45% | +68% | -170% | n/a | n/a | n/a |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $752M | -7% | +8% | 10% | n/a | 9.4% | -1.4% |
| Yabao Pharmaceutical 600351.SS | China | $678M | 0% | -3% | 16% | n/a | -8.3% | -2.8% |
| Guizhou Bailing Group Pharmaceutical 002424.SZ | China | $755M | -20% | -25% | 2% | n/a | 13.5% | -0.2% |
| Youcare Pharmaceutical 688658.SS | China | $674M | -49% | -7% | -13% | 24.9× | n/a | n/a |
| Philogen PHIL.MI | Italy | $672M | -11% | +295% | 79% | 10.1× | n/a | n/a |
| Jiangsu Aidea Pharmaceutical 688488.SS | China | $672M | -35% | +7% | 8% | 112.1× | 31.9% | +19.8% |